loading page

Tumor immune microenvironment in non-small cell lung cancer with EGFR mutation before and after EGFR-TKIs treatment
  • +2
  • chao wang,
  • lihui liu,
  • sini li,
  • hua bai,
  • jie wang
chao wang
Cancer Hospital Chinese Academy of Medical Sciences
Author Profile
lihui liu
Cancer Hospital Chinese Academy of Medical Sciences
Author Profile
sini li
Cancer Hospital Chinese Academy of Medical Sciences
Author Profile
hua bai
Cancer Hospital Chinese Academy of Medical Sciences
Author Profile
jie wang
Cancer Hospital Chinese Academy of Medical Sciences
Author Profile

Abstract

Lung cancer is the most common cancer and a leading cause of death from cancer in men and women in the world. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are considered as the first-line treatment of EGFR mutated NSCLC. However, almost all patients eventually develop acquired resistance to EGFR-TKIs, with a median PFS of 9-14 months. With the development of immunotherapy, people realize that the interaction between tumor immune microenvironment (TIME) and tumor cells can also affect EGFR-TKIs treatment. TIME contains a variety of elements and previous researches of TIME in EGFR-TKIs therapy on NSCLC are decentralized. Here, we review the characteristics of TIME in NSCLC from EGFR-TKIs therapy and its role in TKIs resistance.